[go: up one dir, main page]

AU2002231654A1 - Pharmaceutical paste comprising an acid-labile active ingredient - Google Patents

Pharmaceutical paste comprising an acid-labile active ingredient

Info

Publication number
AU2002231654A1
AU2002231654A1 AU2002231654A AU3165402A AU2002231654A1 AU 2002231654 A1 AU2002231654 A1 AU 2002231654A1 AU 2002231654 A AU2002231654 A AU 2002231654A AU 3165402 A AU3165402 A AU 3165402A AU 2002231654 A1 AU2002231654 A1 AU 2002231654A1
Authority
AU
Australia
Prior art keywords
acid
paste
active ingredient
labile active
labile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002231654A
Other languages
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of AU2002231654A1 publication Critical patent/AU2002231654A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002231654A 2000-12-07 2001-12-05 Pharmaceutical paste comprising an acid-labile active ingredient Abandoned AU2002231654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126828.3 2000-12-07
EP00126828 2000-12-07
PCT/EP2001/014253 WO2002045686A2 (en) 2000-12-07 2001-12-05 Pharmaceutical paste comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
AU2002231654A1 true AU2002231654A1 (en) 2002-06-18

Family

ID=8170595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231654A Abandoned AU2002231654A1 (en) 2000-12-07 2001-12-05 Pharmaceutical paste comprising an acid-labile active ingredient

Country Status (15)

Country Link
US (1) US7988999B2 (ja)
EP (1) EP1341524B1 (ja)
JP (1) JP4241041B2 (ja)
KR (1) KR20030059314A (ja)
CN (1) CN100536844C (ja)
AT (1) ATE529097T1 (ja)
AU (1) AU2002231654A1 (ja)
BR (1) BR0115985A (ja)
CA (1) CA2430816C (ja)
CY (1) CY1112510T1 (ja)
DK (1) DK1341524T3 (ja)
ES (1) ES2375269T3 (ja)
PT (1) PT1341524E (ja)
SI (1) SI1341524T1 (ja)
WO (1) WO2002045686A2 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2403238T3 (es) * 2000-12-07 2013-05-16 Takeda Gmbh Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
BRPI0406427B8 (pt) 2003-03-10 2021-05-25 Astrazeneca Ab processo para a preparação de roflumilast
JP4109286B2 (ja) * 2003-05-02 2008-07-02 順也 藤森 親水性ブレンドゲル
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
EP2462958A3 (en) * 2003-09-23 2012-09-19 Orthocon Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
WO2005074929A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
WO2006097456A1 (en) * 2005-03-16 2006-09-21 Nycomed Gmbh Taste masked dosage form containing roflumilast
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) * 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
NZ576223A (en) 2006-10-10 2012-04-27 Wisconsin Alumni Res Found Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
CN101959527B (zh) * 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
JP5773983B2 (ja) * 2009-04-08 2015-09-02 ウィスコンシン アルムニ リサーチ ファンデイション 乳房内乳頭シール剤及びその熟成チーズの外観上の欠陥を減少又は除去のための使用
EP2526931B1 (en) * 2011-05-23 2014-12-17 Deva Holding Anonim Sirketi Wet granulation methods of cetyl myristate and/or cetyl palmitate
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
EP3999043A4 (en) * 2019-07-19 2023-06-21 SPI Pharma, INC. PRODUCTION OF LIPOPHILIC ACTIVE SUBSTANCES

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
EP0542299B1 (en) * 1991-11-15 1999-08-04 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ester linkage containing polymers for use in pharmaceutical preparations
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US20010051131A1 (en) * 1996-06-19 2001-12-13 Evan C. Unger Methods for delivering bioactive agents
US6156346A (en) * 1997-01-29 2000-12-05 Johns Hopkins University Urease-responsive delivery systems for diagnostic and therapeutic applications
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
PT1037607E (pt) * 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
RS50023B (sr) 1999-02-23 2008-09-29 Merck & Co. Inc., Farmaceutski sastav koji sadrži inhibitore protonske pumpe
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
UA74339C2 (uk) * 1999-06-07 2005-12-15 Алтана Фарма Аг Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
KR20030032922A (ko) * 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6606234B1 (en) * 2000-09-05 2003-08-12 Saint-Gobain Ceramics & Plastics, Inc. Electrostatic chuck and method for forming an electrostatic chuck having porous regions for fluid flow
DK1341528T3 (da) * 2000-12-07 2012-03-26 Nycomed Gmbh Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
AU2002235253A1 (en) * 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophilic active agents
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof

Also Published As

Publication number Publication date
JP2004514733A (ja) 2004-05-20
ES2375269T3 (es) 2012-02-28
CN100536844C (zh) 2009-09-09
BR0115985A (pt) 2003-12-23
PT1341524E (pt) 2011-12-30
EP1341524A2 (en) 2003-09-10
ATE529097T1 (de) 2011-11-15
DK1341524T3 (da) 2012-01-16
KR20030059314A (ko) 2003-07-07
US7988999B2 (en) 2011-08-02
WO2002045686A2 (en) 2002-06-13
WO2002045686A3 (en) 2002-12-12
CY1112510T1 (el) 2015-12-09
CA2430816A1 (en) 2002-06-13
EP1341524B1 (en) 2011-10-19
CN1479611A (zh) 2004-03-03
JP4241041B2 (ja) 2009-03-18
CA2430816C (en) 2012-05-15
US20040101558A1 (en) 2004-05-27
SI1341524T1 (sl) 2012-02-29

Similar Documents

Publication Publication Date Title
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
UA63993C2 (uk) Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
IL150528A0 (en) Ibuprofen containing active agent preparation
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
WO2002087546A3 (en) Method for manufacturing a low dose pharmaceutical composition
MY127350A (en) Flash-melt oral dose formulations
WO2005097076A3 (en) Low dose pharmaceutical products
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
WO2005065639A3 (en) Novel pharmaceutical compositions
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
ATE374600T1 (de) Pharmazeutische formulierung enthaltend olanzapin
CA2429793A1 (en) Interferon therapeutic effect enhancer
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
WO2003013441A3 (en) Levothyroxine compositions and methods
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
WO2004030684A3 (en) Kavalactone product
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
WO2004014318A3 (en) Levothyroxine compositions and methods
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
HU0100122D0 (en) Use of tiludronic acid and derivatives thereof in poultry for preparation of a medicinal product for preventing and treating osteoporosis